{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:57:35Z","timestamp":1762081055406,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-022-09339-5","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T09:05:53Z","timestamp":1671699953000},"page":"4389-4400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response"],"prefix":"10.1007","volume":"33","author":[{"given":"Zhe","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yi","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-6325","authenticated-orcid":false,"given":"Kai-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"9339_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000501501","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo M (2019) Immuno-oncology therapy for hepatocellular carcinoma: current status and ongoing trials. Liver Cancer 8:221\u2013238","journal-title":"Liver Cancer"},{"key":"9339_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940\u2013952","journal-title":"Lancet Oncol"},{"key":"9339_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23:77\u201390","journal-title":"Lancet Oncol"},{"key":"9339_CR4","doi-asserted-by":"crossref","unstructured":"Wei CY, Zhu MX, Zhang PF et al (2022) PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol 77:163\u2013176","DOI":"10.1016\/j.jhep.2022.02.019"},{"key":"9339_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fonc.2020.00353","volume":"10","author":"Y Dong","year":"2020","unstructured":"Dong Y, Zhou L (2020) Xia W, et al Preoperative prediction of microvascular invasion in hepatocellular carcinoma: initial application of a radiomic algorithm based on grayscale ultrasound images. Front Oncol 10:353","journal-title":"Front Oncol"},{"key":"9339_CR6","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3748\/wjg.v22.i42.9279","volume":"22","author":"WM Cong","year":"2016","unstructured":"Cong WM, Bu H, Chen J et al (2016) Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 22:9279\u20139287","journal-title":"World J Gastroenterol"},{"key":"9339_CR7","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"J van Griethuysen","year":"2017","unstructured":"van Griethuysen J, Fedorov A, Parmar C et al (2017) Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res 77:e104\u2013e107","journal-title":"Cancer Res"},{"key":"9339_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295:328\u2013338","journal-title":"Radiology"},{"key":"9339_CR9","doi-asserted-by":"crossref","unstructured":"Tochio H, Sugahara M, Imai Y et al (2015) Hyperenhanced Rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer Cells. Oncology 89(Suppl 2):33\u201341","DOI":"10.1159\/000440629"},{"key":"9339_CR10","doi-asserted-by":"publisher","unstructured":"Arlauckas SP, Garris CS, Kohler RH et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 10;9(389):eaal3604. https:\/\/doi.org\/10.1126\/scitranslmed.aal3604","DOI":"10.1126\/scitranslmed.aal3604"},{"key":"9339_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 68:723\u2013750","journal-title":"Hepatology"},{"key":"9339_CR12","doi-asserted-by":"crossref","unstructured":"Kaseb AO, Cao H, Mohamed YI at al (2020) Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. J Clin Oncol 38:4599","DOI":"10.1200\/JCO.2020.38.15_suppl.4599"},{"key":"9339_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9339_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III Trial. J Clin Oncol 38:193\u2013202","journal-title":"J Clin Oncol"},{"key":"9339_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163\u20131173","journal-title":"Lancet"},{"key":"9339_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1148\/radiol.12120226","volume":"265","author":"A Kitao","year":"2012","unstructured":"Kitao A, Matsui O, Yoneda N et al (2012) Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265:780\u2013789","journal-title":"Radiology"},{"key":"9339_CR17","doi-asserted-by":"crossref","unstructured":"Lee JY, Minami Y, Choi BI et al (2020) The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. J Med Ultrasound 28:59\u201382","DOI":"10.14366\/usg.20057"},{"key":"9339_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ultrasmedbio.2006.08.008","volume":"33","author":"K Yanagisawa","year":"2007","unstructured":"Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H (2007) Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 33:318\u2013325","journal-title":"Ultrasound Med Biol"},{"issue":"Suppl 1","key":"9339_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000173423","volume":"75","author":"K Hatanaka","year":"2008","unstructured":"Hatanaka K, Kudo M, Minami Y, Maekawa K (2008) Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 75(Suppl 1):42\u201347","journal-title":"Oncology"},{"key":"9339_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/jhep.2000.9113","volume":"32","author":"Y Imai","year":"2000","unstructured":"Imai Y, Murakami T, Yoshida S et al (2000) Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 32:205\u2013212","journal-title":"Hepatology"},{"key":"9339_CR21","doi-asserted-by":"crossref","unstructured":"Tanaka H, Iijima H, Higashiura A et al (2013) New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol 49:755\u2013763","DOI":"10.1007\/s00535-013-0830-1"},{"key":"9339_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","volume":"6","author":"H Xiao","year":"2020","unstructured":"Xiao H, Guo Y, Li B et al (2020) M2-Like Tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKK\u03b2 siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects. ACS Cent Sci 6:1208\u20131222","journal-title":"ACS Cent Sci"},{"key":"9339_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D et al (2019) Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68:1653\u20131666","journal-title":"Gut"},{"key":"9339_CR24","doi-asserted-by":"crossref","unstructured":"Exposito MJJ, Akce M, Alvarez JLM et al (2018) CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. Ann Oncol; 29","DOI":"10.1093\/annonc\/mdy432.059"},{"key":"9339_CR25","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"key":"9339_CR26","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","volume":"49","author":"RA Droeser","year":"2013","unstructured":"Droeser RA, Hirt C, Viehl CT et al (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49:2233\u20132242","journal-title":"Eur J Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-09339-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T12:12:02Z","timestamp":1683893522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-09339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["9339"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-09339-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is KaiYan Li.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}